GKOUNTAKOS, ANASTASIOS
 Distribuzione geografica
Continente #
NA - Nord America 409
EU - Europa 324
AS - Asia 140
OC - Oceania 2
AF - Africa 1
SA - Sud America 1
Totale 877
Nazione #
US - Stati Uniti d'America 406
CN - Cina 122
IT - Italia 87
SE - Svezia 58
GB - Regno Unito 56
IE - Irlanda 50
FR - Francia 36
FI - Finlandia 13
DE - Germania 12
KR - Corea 8
UA - Ucraina 8
IR - Iran 4
CA - Canada 3
AU - Australia 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
ES - Italia 1
IL - Israele 1
IN - India 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
NL - Olanda 1
PH - Filippine 1
UZ - Uzbekistan 1
Totale 877
Città #
Chandler 114
Southend 52
Dublin 48
Beijing 39
Verona 32
Jacksonville 27
New York 22
Ann Arbor 15
Ashburn 15
Wilmington 15
Lawrence 14
Princeton 14
Jinan 12
Woodbridge 11
Helsinki 8
Nanjing 8
Seoul 8
Seattle 7
Tianjin 6
Hebei 5
Milan 5
Redmond 5
Redwood City 5
Sindelfingen 5
Cagliari 4
Falls Church 4
Jiaxing 4
Shenyang 4
Zhengzhou 4
Arzignano 3
Brescia 3
Guangzhou 3
Hangzhou 3
Lappeenranta 3
Orlando 3
Rome 3
Boydton 2
Cambridge 2
Chions 2
Dongguan 2
Nanchang 2
Ningbo 2
Pieve di Soligo 2
Riva 2
Sossano 2
Taizhou 2
Toronto 2
Ardabil 1
Augusta 1
Baku 1
Burgas 1
Changsha 1
Charlotte 1
Chicago 1
Dearborn 1
Edinburgh 1
Fremont 1
Fuzhou 1
Haikou 1
Houston 1
Illasi 1
Isola della Scala 1
Kashan 1
Lanzhou 1
Laredo 1
London 1
Los Angeles 1
Madrid 1
Manila 1
Martano 1
Melbourne 1
Messina 1
Miami 1
Minsk 1
Montréal 1
Mumbai 1
Negrar 1
Newark 1
Norwalk 1
Pozza di Fassa 1
San Francisco 1
San Mateo 1
Taiyuan 1
Tashkent 1
Tel Aviv 1
Tolentino 1
Vientiane 1
Washington 1
Zanjan 1
Totale 597
Nome #
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 80
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 68
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 64
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 61
Assessing the potential role of Rictor expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer 58
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 57
Muscle derangement and alteration of the nutritional machinery in NSCLC 56
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 54
Physical activity and exercise in lung cancer care: will promises be fulfilled? 53
Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients 49
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 46
Undifferentiated Sarcomatoid Carcinoma of the Pancreas: From Histology and Molecular Pathology to Precision Oncology 45
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 40
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 37
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic Implications 30
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring / Poorly Cohesive Cells 24
Extrahepatic Distal Cholangiocarcinoma vs. Pancreatic Ductal Adenocarcinoma: Histology and Molecular Profiling for Differential Diagnosis and Treatment 22
Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance 21
An Insight on Functioning Pancreatic Neuroendocrine Neoplasms 20
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 19
An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide 15
Fusion genes in pancreatic tumors 3
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives 2
Totale 924
Categoria #
all - tutte 3.732
article - articoli 3.126
book - libri 0
conference - conferenze 436
curatela - curatele 0
other - altro 170
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.464


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20196 0 0 0 0 0 0 0 0 0 0 1 5
2019/202087 6 1 1 3 10 4 6 11 15 9 7 14
2020/2021107 9 11 2 22 14 13 3 3 3 3 13 11
2021/2022136 7 40 4 12 6 2 2 16 10 1 8 28
2022/2023329 16 37 24 52 30 60 7 24 60 1 8 10
2023/2024210 10 23 29 19 24 35 22 27 5 16 0 0
Totale 924